Compare NAC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAC | MLYS |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1998 | 2023 |
| Metric | NAC | MLYS |
|---|---|---|
| Price | $10.16 | $20.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $46.33 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.80 | $20.41 |
| 52 Week High | $12.25 | $47.65 |
| Indicator | NAC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 32.24 |
| Support Level | $9.80 | N/A |
| Resistance Level | $12.04 | $31.19 |
| Average True Range (ATR) | 0.17 | 1.27 |
| MACD | 0.04 | -0.29 |
| Stochastic Oscillator | 66.38 | 4.06 |
Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.